Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
House Freedom Caucus bid to censure Democrat over...
Popular TP-Link routers could be banned after risks...
Trump signs off on possible CIA operations in...
Senate unanimously passes Epstein files bill, sends to...
DAVID MARCUS: What Ro Khanna told me about...
Trump official fires back at Dem’s Epstein donor...
Scathing report calls on US to label Islamist...
Nancy Mace to force censure vote against fellow...
Rubio orders restitution for hundreds of staffers denied...
Federal judge calls Comey indictment into question, asks...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Business

Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy

by admin September 11, 2025
September 11, 2025
Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy

Shares of Kenvue fell more than 10% on Friday after a report that Health Secretary Robert F. Kennedy Jr. will likely link autism to the use of the company’s pain medication Tylenol in pregnant women.

HHS will release the report that could draw that link this month, The Wall Street Journal reported on Friday.

That report will also suggest a medicine derived from folate — a water-soluble vitamin — can be used to treat symptoms of the developmental disorder in some people, according to the Journal.

In a statement, an HHS spokesperson said, “We are using gold-standard science to get to the bottom of America’s unprecedented rise in autism rates.”

“Until we release the final report, any claims about its contents are nothing more than speculation,” they added.

Tylenol could be the latest widely used and accepted treatment that Kennedy has undermined at the helm of HHS, which oversees federal health agencies that regulate drugs and other therapies. Kennedy has also taken steps to change vaccine policy in the U.S., and has amplified false claims about safe and effective shots that use mRNA technology.

Kennedy has made the disorder a key focus of HHS, pledging in April that the agency will “know what has caused the autism epidemic” by September and eliminate exposures. He also said that month that the agency has launched a “massive testing and research effort” involving hundreds of scientists worldwide that will determine the cause.

In a statement, Kenvue said it has “continuously evaluated the science and [continues] to believe there is no causal link” between the use of acetaminophen, the generic name for Tylenol, during pregnancy and autism.

The company added that the Food and Drug Administration and leading medical organizations “agree on the safety” of the drug, its use during pregnancy and the information provided on the Tylenol label.

The FDA website says the agency has not found “clear evidence” that appropriate use of acetaminophen during pregnancy causes “adverse pregnancy, birth, neurobehavioral, or developmental outcomes.” But the FDA said it advises pregnant women to speak with their health-care providers before using over-the-counter drugs.

The American College of Obstetricians and Gynecologists maintains that acetaminophen is safe during pregnancy when taken as directed and after consulting a health-care provider.

Some previous studies have suggested the drug poses risks to fetal development, and some parents have brought lawsuits claiming that they gave birth to children with autism after using it.

But a federal judge in Manhattan ruled in 2023 that some of those lawsuits lacked scientific evidence and later ended the litigation in 2024. Some research has also found no association between acetaminophen use and autism.

In a note on Friday, BNP Paribas analyst Navann Ty said the firm believes the “hurdle to proving causation [between the drug and autism] is high, particularly given that the litigation previously concluded in Kenvue’s favor.”

This post appeared first on NBC NEWS

previous post
Trump administration ramps up pressure on Labor Department with data probe
next post
Paramount mandates 5-day-a-week return to office ahead of major cost cuts

You may also like

Why an indicator that has foretold almost every...

July 25, 2024

Tariffs or not, a Chinese baby products company...

May 21, 2025

Elon Musk’s X sues advertisers over alleged ‘massive...

August 7, 2024

Dollar General tests same-day delivery as discounter chases...

December 7, 2024

Microsoft says goodbye to the Windows blue screen...

June 30, 2025

Pfizer CEO says tariff uncertainty is deterring further...

May 2, 2025

Trump transfers all his DJT shares to his...

December 21, 2024

McDonald’s Snack Wrap is officially making a permanent...

June 5, 2025

Sports executive charged with bid-rigging in Texas arena...

July 11, 2025

Kohl’s CEO Tom Kingsbury to step down and...

November 27, 2024

Recent Posts

  • House Freedom Caucus bid to censure Democrat over Epstein links goes down in flames
  • Popular TP-Link routers could be banned after risks exposed
  • Trump signs off on possible CIA operations in Venezuela: report
  • Senate unanimously passes Epstein files bill, sends to Trump’s desk
  • DAVID MARCUS: What Ro Khanna told me about his party’s future and Biden’s 20M illegals

    Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (951)
    • Investing (3,465)
    • Politics (4,229)
    • Stock (4)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 Sightful Invest. All Rights Reserved.